IRGD (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "IRGD" in English language version.

refsWebsite

Global rank English rank

10nih.gov

4^th place

6doi.org

2^nd place

3harvard.edu

18^th place

17^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1globenewswire.com

2,614^th place

1,549^th place

clinicaltrials.gov

Clinical trial number NCT03517176 for "CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer" at ClinicalTrials.gov

doi.org

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. (May 2010). "Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs". Science. 328 (5981): 1031–1035. Bibcode:2010Sci...328.1031S. doi:10.1126/science.1183057. PMC 2881692. PMID 20378772.
Ding N, Zou Z, Sha H, Su S, Qian H, Meng F, et al. (March 2019). "iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer". Nature Communications. 10 (1): 1336. Bibcode:2019NatCo..10.1336D. doi:10.1038/s41467-019-09296-6. PMC 6430780. PMID 30902997.
Ruoslahti E (February 2017). "Tumor penetrating peptides for improved drug delivery". Advanced Drug Delivery Reviews. 110–111: 3–12. doi:10.1016/j.addr.2016.03.008. PMC 5045823. PMID 27040947.
Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (September 2009). "C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration". Proceedings of the National Academy of Sciences of the United States of America. 106 (38): 16157–16162. Bibcode:2009PNAS..10616157T. doi:10.1073/pnas.0908201106. PMC 2752543. PMID 19805273.
Haas MJ (29 April 2010). "Coupled, but not conjugated, in cancer". SciBX: Science-Business EXchange. 3 (17): 514. doi:10.1038/scibx.2010.514.
Ruoslahti E (May 2017). "Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier". The Journal of Clinical Investigation. 127 (5): 1622–1624. doi:10.1172/JCI93955. PMC 5409784. PMID 28414298.

globenewswire.com

"Cend Therapeutics' CEND-1 Granted Fast Track Designation for Pancreatic Cancer" (Press release). Retrieved 2021-10-01.

harvard.edu

ui.adsabs.harvard.edu

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. (May 2010). "Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs". Science. 328 (5981): 1031–1035. Bibcode:2010Sci...328.1031S. doi:10.1126/science.1183057. PMC 2881692. PMID 20378772.
Ding N, Zou Z, Sha H, Su S, Qian H, Meng F, et al. (March 2019). "iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer". Nature Communications. 10 (1): 1336. Bibcode:2019NatCo..10.1336D. doi:10.1038/s41467-019-09296-6. PMC 6430780. PMID 30902997.
Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (September 2009). "C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration". Proceedings of the National Academy of Sciences of the United States of America. 106 (38): 16157–16162. Bibcode:2009PNAS..10616157T. doi:10.1073/pnas.0908201106. PMC 2752543. PMID 19805273.

nih.gov

ncbi.nlm.nih.gov

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. (May 2010). "Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs". Science. 328 (5981): 1031–1035. Bibcode:2010Sci...328.1031S. doi:10.1126/science.1183057. PMC 2881692. PMID 20378772.
Ding N, Zou Z, Sha H, Su S, Qian H, Meng F, et al. (March 2019). "iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer". Nature Communications. 10 (1): 1336. Bibcode:2019NatCo..10.1336D. doi:10.1038/s41467-019-09296-6. PMC 6430780. PMID 30902997.
Ruoslahti E (February 2017). "Tumor penetrating peptides for improved drug delivery". Advanced Drug Delivery Reviews. 110–111: 3–12. doi:10.1016/j.addr.2016.03.008. PMC 5045823. PMID 27040947.
Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (September 2009). "C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration". Proceedings of the National Academy of Sciences of the United States of America. 106 (38): 16157–16162. Bibcode:2009PNAS..10616157T. doi:10.1073/pnas.0908201106. PMC 2752543. PMID 19805273.
Ruoslahti E (May 2017). "Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier". The Journal of Clinical Investigation. 127 (5): 1622–1624. doi:10.1172/JCI93955. PMC 5409784. PMID 28414298.

pubmed.ncbi.nlm.nih.gov

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. (May 2010). "Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs". Science. 328 (5981): 1031–1035. Bibcode:2010Sci...328.1031S. doi:10.1126/science.1183057. PMC 2881692. PMID 20378772.
Ding N, Zou Z, Sha H, Su S, Qian H, Meng F, et al. (March 2019). "iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer". Nature Communications. 10 (1): 1336. Bibcode:2019NatCo..10.1336D. doi:10.1038/s41467-019-09296-6. PMC 6430780. PMID 30902997.
Ruoslahti E (February 2017). "Tumor penetrating peptides for improved drug delivery". Advanced Drug Delivery Reviews. 110–111: 3–12. doi:10.1016/j.addr.2016.03.008. PMC 5045823. PMID 27040947.
Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (September 2009). "C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration". Proceedings of the National Academy of Sciences of the United States of America. 106 (38): 16157–16162. Bibcode:2009PNAS..10616157T. doi:10.1073/pnas.0908201106. PMC 2752543. PMID 19805273.
Ruoslahti E (May 2017). "Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier". The Journal of Clinical Investigation. 127 (5): 1622–1624. doi:10.1172/JCI93955. PMC 5409784. PMID 28414298.